Reeve Emma's most recent trade in PTC Therapeutics Inc was a trade of 4,000 Common Stock done . Disclosure was reported to the exchange on Jan. 2, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| PTC Therapeutics Inc | Emma Reeve | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 4,000 | 10,666 (0%) | 0% | 0 | Common Stock | |
| PTC Therapeutics Inc | Emma Reeve | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 3,475 | 3,475 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Emma Reeve | Director | Sale of securities on an exchange or to another person at price $ 76.00 per share. | 02 Jan 2026 | 734 | 10,666 (0%) | 0% | 76 | 55,784 | Common Stock |
| PTC Therapeutics Inc | Emma Reeve | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 734 | 0 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Emma Reeve | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 46.54 per share. | 02 Jan 2026 | 734 | 11,400 (0%) | 0% | 46.5 | 34,160 | Common Stock |
| PTC Therapeutics Inc | Emma Reeve | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Dec 2025 | 733 | 734 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Emma Reeve | Director | Sale of securities on an exchange or to another person at price $ 78.62 per share. | 03 Dec 2025 | 733 | 6,666 (0%) | 0% | 78.6 | 57,628 | Common Stock |
| PTC Therapeutics Inc | Emma Reeve | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 46.54 per share. | 03 Dec 2025 | 733 | 7,399 (0%) | 0% | 46.5 | 34,114 | Common Stock |
| PTC Therapeutics Inc | Emma Reeve | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Nov 2025 | 10,000 | 0 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Emma Reeve | Director | Sale of securities on an exchange or to another person at price $ 79.50 per share. | 21 Nov 2025 | 10,000 | 6,666 (0%) | 0% | 79.5 | 795,000 | Common Stock |
| PTC Therapeutics Inc | Emma Reeve | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 51.16 per share. | 21 Nov 2025 | 10,000 | 16,666 (0%) | 0% | 51.2 | 511,600 | Common Stock |
| PTC Therapeutics Inc | Emma Reeve | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Nov 2025 | 7,333 | 1,467 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Emma Reeve | Director | Sale of securities on an exchange or to another person at price $ 74.50 per share. | 12 Nov 2025 | 7,333 | 6,666 (0%) | 0% | 74.5 | 546,309 | Common Stock |
| PTC Therapeutics Inc | Emma Reeve | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 46.54 per share. | 12 Nov 2025 | 7,333 | 13,999 (0%) | 0% | 46.5 | 341,278 | Common Stock |
| PTC Therapeutics Inc | Emma Reeve | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Oct 2025 | 12,000 | 0 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Emma Reeve | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 38.10 per share. | 30 Oct 2025 | 12,000 | 18,666 (0%) | 0% | 38.1 | 457,200 | Common Stock |
| PTC Therapeutics Inc | Emma Reeve | Director | Sale of securities on an exchange or to another person at price $ 69.50 per share. | 30 Oct 2025 | 12,000 | 6,666 (0%) | 0% | 69.5 | 834,000 | Common Stock |
| PTC Therapeutics Inc | Emma Reeve | Director | Sale of securities on an exchange or to another person at price $ 69.50 per share. | 30 Oct 2025 | 3,666 | 6,666 (0%) | 0% | 69.5 | 254,787 | Common Stock |
| PTC Therapeutics Inc | Emma Reeve | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Oct 2025 | 10,000 | 0 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Emma Reeve | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 39.42 per share. | 03 Oct 2025 | 10,000 | 20,332 (0%) | 0% | 39.4 | 394,200 | Common Stock |
| PTC Therapeutics Inc | Emma Reeve | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 33.63 per share. | 03 Oct 2025 | 8,650 | 18,982 (0%) | 0% | 33.6 | 290,900 | Common Stock |
| PTC Therapeutics Inc | Emma Reeve | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Oct 2025 | 8,650 | 0 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Emma Reeve | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 33.02 per share. | 03 Oct 2025 | 6,912 | 17,244 (0%) | 0% | 33.0 | 228,234 | Common Stock |
| PTC Therapeutics Inc | Emma Reeve | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Oct 2025 | 6,912 | 0 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Emma Reeve | Director | Sale of securities on an exchange or to another person at price $ 66.09 per share. | 03 Oct 2025 | 4,591 | 12,713 (0%) | 0% | 66.1 | 303,419 | Common Stock |
| PTC Therapeutics Inc | Emma Reeve | Director | Sale of securities on an exchange or to another person at price $ 66.10 per share. | 03 Oct 2025 | 4,037 | 12,216 (0%) | 0% | 66.1 | 266,846 | Common Stock |
| PTC Therapeutics Inc | Emma Reeve | Director | Sale of securities on an exchange or to another person at price $ 66.11 per share. | 03 Oct 2025 | 3,149 | 11,932 (0%) | 0% | 66.1 | 208,180 | Common Stock |
| PTC Therapeutics Inc | Emma Reeve | Director | Sale of securities on an exchange or to another person at price $ 65.09 per share. | 03 Oct 2025 | 3,028 | 17,304 (0%) | 0% | 65.1 | 197,093 | Common Stock |
| PTC Therapeutics Inc | Emma Reeve | Director | Sale of securities on an exchange or to another person at price $ 65.05 per share. | 03 Oct 2025 | 2,729 | 16,253 (0%) | 0% | 65.0 | 177,521 | Common Stock |
| PTC Therapeutics Inc | Emma Reeve | Director | Sale of securities on an exchange or to another person at price $ 66.87 per share. | 03 Oct 2025 | 2,381 | 10,332 (0%) | 0% | 66.9 | 159,217 | Common Stock |
| PTC Therapeutics Inc | Emma Reeve | Director | Sale of securities on an exchange or to another person at price $ 65.02 per share. | 03 Oct 2025 | 2,163 | 15,081 (0%) | 0% | 65.0 | 140,638 | Common Stock |
| PTC Therapeutics Inc | Emma Reeve | Director | Sale of securities on an exchange or to another person at price $ 66.89 per share. | 03 Oct 2025 | 1,884 | 10,332 (0%) | 0% | 66.9 | 126,021 | Common Stock |
| PTC Therapeutics Inc | Emma Reeve | Director | Sale of securities on an exchange or to another person at price $ 66.93 per share. | 03 Oct 2025 | 1,600 | 10,332 (0%) | 0% | 66.9 | 107,088 | Common Stock |
| PTC Therapeutics Inc | Emma Reeve | Director | Sale of securities on an exchange or to another person at price $ 59.50 per share. | 11 Sep 2025 | 10,000 | 10,332 (0%) | 0% | 59.5 | 595,000 | Common Stock |
| PTC Therapeutics Inc | Emma Reeve | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 25.69 per share. | 11 Sep 2025 | 10,000 | 20,332 (0%) | 0% | 25.7 | 256,900 | Common Stock |
| PTC Therapeutics Inc | Emma Reeve | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Sep 2025 | 10,000 | 0 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Emma Reeve | Director | Sale of securities on an exchange or to another person at price $ 59.50 per share. | 11 Sep 2025 | 3,534 | 11,666 (0%) | 0% | 59.5 | 210,273 | Common Stock |
| PTC Therapeutics Inc | Emma Reeve | Director | Sale of securities on an exchange or to another person at price $ 59.50 per share. | 11 Sep 2025 | 1,334 | 10,332 (0%) | 0% | 59.5 | 79,373 | Common Stock |
| PTC Therapeutics Inc | Emma Reeve | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Sep 2025 | 837 | 0 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Emma Reeve | Director | Sale of securities on an exchange or to another person at price $ 59.50 per share. | 11 Sep 2025 | 837 | 10,332 (0%) | 0% | 59.5 | 49,802 | Common Stock |
| PTC Therapeutics Inc | Emma Reeve | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 33.63 per share. | 11 Sep 2025 | 837 | 11,169 (0%) | 0% | 33.6 | 28,148 | Common Stock |
| Whitehawk Therapeutics Inc | Emma Reeve | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2025 | 40,006 | 40,006 | - | - | Stock Option (right to buy) | |
| PTC Therapeutics Inc | Emma Reeve | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 8,800 | 8,800 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Emma Reeve | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 4,000 | 15,200 (0%) | 0% | 0 | Common Stock | |
| Whitehawk Therapeutics Inc | Emma Reeve | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 45,832 | 45,832 | - | - | Stock Option (right to buy) | |
| Editas Medicine Inc | Emma Reeve | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 May 2024 | 25,000 | 25,000 | - | - | Stock Option (right to buy) | |
| PTC Therapeutics Inc | Emma Reeve | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Reeve Emma | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 4,000 | 11,200 (0%) | 0% | 0 | Common Stock | |
| Whitehawk Therapeutics Inc | Emma Reeve | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2023 | 28,255 | 28,255 | - | - | Stock Option (right to buy) | |
| Editas Medicine Inc | Emma Reeve | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 25,000 | 25,000 | - | - | Stock Option (right to buy) | |
| PTC Therapeutics Inc | Emma Reeve | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 May 2023 | 3,948 | 10,052 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Emma Reeve | Director | Sale of securities on an exchange or to another person at price $ 59.53 per share. | 22 May 2023 | 3,948 | 7,200 (0%) | 0% | 59.5 | 235,030 | Common Stock |
| PTC Therapeutics Inc | Emma Reeve | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 33.63 per share. | 22 May 2023 | 3,948 | 11,148 (0%) | 0% | 33.6 | 132,771 | Common Stock |
| PTC Therapeutics Inc | Emma Reeve | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 May 2023 | 2,995 | 8,005 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Emma Reeve | Director | Sale of securities on an exchange or to another person at price $ 59.53 per share. | 22 May 2023 | 2,995 | 7,200 (0%) | 0% | 59.5 | 178,303 | Common Stock |
| PTC Therapeutics Inc | Emma Reeve | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 33.02 per share. | 22 May 2023 | 2,995 | 10,195 (0%) | 0% | 33.0 | 98,895 | Common Stock |
| PTC Therapeutics Inc | Emma Reeve | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 May 2023 | 1,402 | 8,650 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Emma Reeve | Director | Sale of securities on an exchange or to another person at price $ 59.54 per share. | 22 May 2023 | 1,402 | 7,200 (0%) | 0% | 59.5 | 83,472 | Common Stock |
| PTC Therapeutics Inc | Emma Reeve | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 33.63 per share. | 22 May 2023 | 1,402 | 8,602 (0%) | 0% | 33.6 | 47,149 | Common Stock |
| PTC Therapeutics Inc | Emma Reeve | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 May 2023 | 1,093 | 6,912 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Emma Reeve | Director | Sale of securities on an exchange or to another person at price $ 59.53 per share. | 22 May 2023 | 1,093 | 7,200 (0%) | 0% | 59.5 | 65,068 | Common Stock |
| PTC Therapeutics Inc | Emma Reeve | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 33.02 per share. | 22 May 2023 | 1,093 | 8,293 (0%) | 0% | 33.0 | 36,091 | Common Stock |
| PTC Therapeutics Inc | Emma Reeve | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 May 2023 | 173 | 994 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Emma Reeve | Director | Sale of securities on an exchange or to another person at price $ 59.53 per share. | 22 May 2023 | 173 | 7,200 (0%) | 0% | 59.5 | 10,298 | Common Stock |
| PTC Therapeutics Inc | Emma Reeve | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 33.63 per share. | 22 May 2023 | 173 | 7,373 (0%) | 0% | 33.6 | 5,818 | Common Stock |
| PTC Therapeutics Inc | Emma Reeve | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 May 2023 | 157 | 837 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Emma Reeve | Director | Sale of securities on an exchange or to another person at price $ 59.52 per share. | 22 May 2023 | 157 | 7,200 (0%) | 0% | 59.5 | 9,344 | Common Stock |
| PTC Therapeutics Inc | Emma Reeve | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 33.63 per share. | 22 May 2023 | 157 | 7,357 (0%) | 0% | 33.6 | 5,280 | Common Stock |
| PTC Therapeutics Inc | Emma Reeve | Director | Sale of securities on an exchange or to another person at price $ 55.04 per share. | 21 Apr 2023 | 4,228 | 7,300 (0%) | 0% | 55.0 | 232,701 | Common Stock |
| PTC Therapeutics Inc | Emma Reeve | Director | Sale of securities on an exchange or to another person at price $ 55.57 per share. | 21 Apr 2023 | 100 | 7,200 (0%) | 0% | 55.6 | 5,557 | Common Stock |
| PTC Therapeutics Inc | Emma Reeve | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2023 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Emma Reeve | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2023 | 4,000 | 11,528 (0%) | 0% | 0 | Common Stock | |
| Whitehawk Therapeutics Inc | Emma Reeve | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 18,573 | 18,573 | - | - | Stock Option (right to buy) | |
| Editas Medicine Inc | Emma Reeve | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 25,000 | 25,000 | - | - | Stock Option (right to buy) | |
| PTC Therapeutics Inc | Emma Reeve | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2022 | 12,000 | 12,000 | - | - | Stock Option (Right To Buy) | |
| PTC Therapeutics Inc | Emma Reeve | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2022 | 3,200 | 7,528 (0%) | 0% | 0 | Common Stock | |
| Whitehawk Therapeutics Inc | Emma Reeve | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Sep 2021 | 16,486 | 16,486 | - | - | Stock option (right to buy) | |
| Editas Medicine Inc | Emma Reeve | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Sep 2021 | 13,736 | 13,736 | - | - | Stock Option (right to buy) |